Back

A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors

31 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Risk factors and prevention Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor R. Yalamanchi (Chennai, IN)
Abstract Video
Presentation thumbnail
Associate Professor F. Guerra (Ancona, IT)
Abstract Video
Presentation thumbnail
Doctor P. Sobieraj (Warsaw, PL)
Abstract
Presentation thumbnail
Doctor M. Tan (London, GB)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Risk factors and prevention

The Event

Event poster

ESC Congress 2025

31 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Presentation
Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
thumbnail
Congress Presentation
Therapeutic gaps in low-density lipoprotein cholesterol management have narrowed over time but remain wide: a wide study of 40,141 acute coronary syndrome patients from 2016 to 2021

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources